Aygun Banu, Mortier Nicole A, Kesler Karen, Lockhart Alexandre, Schultz William H, Cohen Alan R, Alvarez Ofelia, Rogers Zora R, Kwiatkowski Janet L, Miller Scott T, Sylvestre Pamela, Iyer Rathi, Lane Peter A, Ware Russell E
Steven and Alexandra Cohen Children's Medical Center, New Hyde Park, NY, USA.
Br J Haematol. 2015 Apr;169(2):262-6. doi: 10.1111/bjh.13280. Epub 2015 Jan 22.
Serial phlebotomy was performed on sixty children with sickle cell anaemia, stroke and transfusional iron overload randomized to hydroxycarbamide in the Stroke With Transfusions Changing to Hydroxyurea trial. There were 927 phlebotomy procedures with only 33 adverse events, all of which were grade 2. Among 23 children completing 30 months of study treatment, the net iron balance was favourable (-8·7 mg Fe/kg) with significant decrease in ferritin, although liver iron concentration remained unchanged. Therapeutic phlebotomy was safe and well-tolerated, with net iron removal in most children who completed 30 months of protocol-directed treatment.
在“输血治疗转变为羟基脲治疗的镰状细胞贫血、中风及输血性铁过载患儿”试验中，对60名患有镰状细胞贫血、中风和输血性铁过载且被随机分配接受羟基脲治疗的儿童进行了系列静脉放血术。共进行了927次静脉放血操作，仅有33例不良事件，所有不良事件均为2级。在完成30个月研究治疗的23名儿童中，净铁平衡良好（-8.7mg铁/千克），铁蛋白显著降低，尽管肝脏铁浓度保持不变。治疗性静脉放血术安全且耐受性良好，在大多数完成30个月方案指导治疗的儿童中实现了净铁清除。
